VKTX Stock Recent News

VKTX LATEST HEADLINES

VKTX Stock News Image - fool.com

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

fool.com 2024 Oct 07
VKTX Stock News Image - zacks.com

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.

zacks.com 2024 Oct 04
VKTX Stock News Image - investors.com

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

investors.com 2024 Oct 04
VKTX Stock News Image - zacks.com

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $64.11, marking a -0.9% move from the previous day.

zacks.com 2024 Oct 03
VKTX Stock News Image - benzinga.com

Viking Therapeutics VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.

benzinga.com 2024 Oct 02
VKTX Stock News Image - fool.com

An analyst waxed bullish on the company's leading pipeline program.

fool.com 2024 Sep 30
VKTX Stock News Image - fool.com

Investors have piled into the biotech because of its weight-loss drug candidate. There are already some hugely successful products on pharmacy shelves.

fool.com 2024 Sep 29
VKTX Stock News Image - fool.com

Viking Therapeutics and Summit Therapeutics both have potential blockbusters on their hands. Their shares have soared this year on the back of strong clinical progress.

fool.com 2024 Sep 28
VKTX Stock News Image - zacks.com

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.

zacks.com 2024 Sep 27
VKTX Stock News Image - marketbeat.com

Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms.

marketbeat.com 2024 Sep 27
10 of 50